These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26731131)

  • 1. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
    Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
    J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
    Suryanarayanan V; Singh SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another One (of the "Undruggable" Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP.
    Kodadek T
    Biochemistry; 2018 Feb; 57(6):899-900. PubMed ID: 29244478
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.
    Hu P; Wang X; Zhang B; Zhang S; Wang Q; Wang Z
    ChemMedChem; 2014 May; 9(5):928-31. PubMed ID: 24474698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain.
    Suryanarayanan V; Rajavel T; Devi KP; Singh SK
    Int J Biol Macromol; 2018 Dec; 120(Pt A):823-834. PubMed ID: 30118769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
    Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
    J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
    Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
    Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
    Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
    Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of PCAF suppresses microglial-mediated β-amyloid neurotoxicity.
    Park SY; Lee YH; Seong AR; Lee J; Jun W; Yoon HG
    Int J Mol Med; 2013 Aug; 32(2):469-75. PubMed ID: 23740527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
    Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
    Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
    Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
    Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
    Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
    Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Labeling of the CBP/p300 KIX Domain for
    Gee CT; Arntson KE; Koleski EJ; Staebell RL; Pomerantz WCK
    Chembiochem; 2018 May; 19(9):963-969. PubMed ID: 29430847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
    Humphreys PG; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Hayhow TG; Hussain J; Jones KL; Lindon M; Michon AM; Renaux JF; Suckling CJ; Tough DF; Prinjha RK
    J Med Chem; 2017 Jan; 60(2):695-709. PubMed ID: 28002667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
    Bronner SM; Murray J; Romero FA; Lai KW; Tsui V; Cyr P; Beresini MH; de Leon Boenig G; Chen Z; Choo EF; Clark KR; Crawford TD; Jayaram H; Kaufman S; Li R; Li Y; Liao J; Liang X; Liu W; Ly J; Maher J; Wai J; Wang F; Zheng A; Zhu X; Magnuson S
    J Med Chem; 2017 Dec; 60(24):10151-10171. PubMed ID: 29155580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
    Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
    J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.